Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
The DOI matches its Crossref record; 281 of the 281 references it cites were found in a registry or an index.
Abstract
Epigenetic aberrations, which are recognized as key drivers of several human diseases, are often caused by genetic defects that result in functional deregulation of epigenetic proteins, their altered expression and/or their atypical recruitment to certain gene promoters. Importantly, epigenetic changes are reversible, and epigenetic enzymes and regulatory proteins can be targeted using small molecules. This Review discusses the role of altered expression and/or function of one class of epigenetic regulators--histone deacetylases (HDACs)--and their role in cancer, neurological diseases and immune disorders. We highlight the development of small-molecule HDAC inhibitors and their use in the laboratory, in preclinical models and in the clinic.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is increasing evidence that KDAC inhibitors work best in combination with other therapies [28–30]”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [29]
In the citing paper
“Growing evidence supports that epigenetic dysregulation through histone deacetylases (HDACs) plays a critical role in synaptic dysfunction and memory loss in Alzheimer’s disease”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [4]
In the citing paper
“HDAC inhibitors can enhance histone acetylation and ameliorate cognitive impairments in various AD models, and HDAC inhibition has been recognized as an attractive therapeutic strategy for AD [4, 5, 7].”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [4]
In the citing paper
“HDAC inhibitors can enhance histone acetylation and ameliorate cognitive impairments in various AD models, and HDAC inhibition has been recognized as an attractive therapeutic strategy for AD [4, 5, 7].”
From CI-994 is a dual modulator of class I HDACs and Wnt/β-catenin signaling for the treatment of Alzheimer's disease (2026) · cites this paper as [4]
In the citing paper
“HDACs are epigenetic modulators that deacetylate lysine residues in histone and nonhistone substrates and their inhibition has attracted much interest for the treatment of neurodegenerative disorders, as several isoforms seem to be implicated in AD memory-related dysfunction: HDAC2 is a nuclear isoform that reduce transcription of CREB-regulated genes involved in learning and memory, HDAC6 targets”
From From combinations to multitarget-directed ligands: A continuum in Alzheimer’s disease polypharmacology (2021) · cites this paper as [118]
Citations
Cites
4 retracted
Zhang, X., Zhao, X., Fiskus, W., Lin, J., Lwin, T., Rao, R., Zhang, Y., Chan, J. C., Fu, K., Marquez, V. E., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.003 · Cited by 276
RetractedChen, C.-S., Wang, Y.-C., Yang, H.-C., Huang, P.-H., Kulp, S. K., Yang, C.-C., Lu, Y.-S., Matsuyama, S., Chen, C.-Y., & Chen, C.-S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3996 · Cited by 187
RetractedDasmahapatra, G. P., Lembersky, D., Kramer, L. B., Fisher, R. I., Friedberg, J. W., Dent, P., & Grant, S. (2010) · Blood · doi:10.1182/blood-2009-12-257261 · Cited by 115
RetractedDasmahapatra, G. P., Lembersky, D., Son, M. P., Attkisson, E., Dent, P., Fisher, R. I., Friedberg, J. W., & Grant, S. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1108 · Cited by 62
RetractedChromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
Jaenisch, R., & Bird, A. (2003) · Nature Genetics · doi:10.1038/ng1089 · Cited by 6,325
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262 · cited 3×
“AML1 and the AML1–ETO fusion protein in the pathogenesis of t(8;21) AML.”
BackgroundLysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Cancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203
Cited by
Items 601–700 of 1,003
Mutations of Chromatin Structure Regulating Genes in Human Malignancies
Chen, J., Herlong, H. F., Stroehlein, J. R., & Mishra, L. (2016) · Current Protein and Peptide Science · doi:10.2174/1389203717666160122120008 · Cited by 35
Virtual screening and experimental validation of novel histone deacetylase inhibitors
Huang, Y., Zhao, J., Song, Q., Zheng, L., Fan, C., Liu, T., Bao, Y., Sun, L., Zhang, L., & Li, Y. (2016) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-016-0075-8 · Cited by 35
Recent advances of dual FGFR inhibitors as a novel therapy for cancer
Liang, Q., Wang, J., Zhao, L., Hou, J., Hu, Y., & Shi, J. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113205 · Cited by 32
Zhao, C., Chen, S., Chen, D., Río-Bergé, C., Zhang, J., van der Wouden, P. E., Daemen, T., & Dekker, F. J. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202310059 · Cited by 37
Common variants near IKZF1 are associated with primary Sjögren's syndrome in Han Chinese
Qu, S., Du, Y., Chang, S., Guo, L., Fang, K., Li, Y., Zhang, F., Zhang, K., & Wang, J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177320 · Cited by 32
In Silico and in Vitro Interactions between Short Chain Fatty Acids and Human Histone Deacetylases
Ho, R. H., Chan, J. C. Y., Fan, H., Kioh, D. Y. Q., Lee, B. W., & Chan, E. C. Y. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b00508 · Cited by 35
Xu, J., Sun, J., Wang, P., Ma, X., & Li, S. (2017) · Journal of drug targeting · doi:10.1080/1061186x.2017.1419355 · Cited by 31
Xia, S., Sun, Q., Zou, Z., Liu, Y., Fang, X., Sun, B., Wei, S., Wang, D., Zhang, A., & Liu, Q. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.39351 · Cited by 34
The impact of autophagy during the development and survival of glioblastoma
Simpson, J. E., & Gammoh, N. (2020) · Open Biology · doi:10.1098/rsob.200184 · Cited by 37
“Targeting HDAC activity is an emerging anti-cancer approach likely to exert its effects through the regulation of gene expression and chromatin remodelling [139].”
BackgroundLi, Y., Liu, Y., Zhao, N., Yang, X., Li, Y., Zhai, F., Zang, X., & Cui, W. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02968-y · Cited by 30
Rapid In Vivo Validation of HDAC Inhibitor-Based Treatments in Neuroblastoma Zebrafish Xenografts
Wrobel, J. K., Najafi, S., Ayhan, S., Gatzweiler, C., Krunic, D., Ridinger, J., Milde, T., Westermann, F., Peterziel, H., Meder, B., et al. (2020) · Pharmaceuticals · doi:10.3390/ph13110345 · Cited by 30
“, vorinostat for cutaneous T-cell lymphoma, panobinostat for multiple myeloma), and clinical trials investigating their utility in solid tumors, both as single agents and in combination with chemotherapeutics, are ongoing [30,39,40].”
BackgroundThe role of SOX family in cancer stem cell maintenance: With a focus on SOX2
Pouremamali, F., Vahedian, V., Hassani, N., Mirzaei, S., Pouremamali, A., Kazemzadeh, H., Faridvand, Y., Jafari-Gharabaghlou, D., Nouri, M., & Maroufi, N. F. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.153783 · Cited by 36
Cadet, J., McCoy, M., & Jayanthi, S. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.345 · Cited by 31
Narita, K., 松原圭介, Itoh, J., Akiyama, Y., Dan, S., Yamori, T., Ito, A., Yoshida, M., & Katoh, T. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.05.031 · Cited by 34
Integrating Epigenomics into the Understanding of Biomedical Insight
Han, Y., & He, X. (2016) · Bioinformatics and Biology Insights · doi:10.4137/bbi.s38427 · Cited by 32
Chen, Y.-J., Wang, W., Wu, W., Hsu, C., Wei, L.-R., Wang, S., Hsu, Y.-W., Liaw, C., & Tsai, W.-C. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183368 · Cited by 33
Chaiyawat, P., Pruksakorn, D., Phanphaisarn, A., Teeyakasem, P., Klangjorhor, J., & Settakorn, J. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.125 · Cited by 30
Therapeutic Opportunities of Targeting Histone Deacetylase Isoforms to Eradicate Cancer Stem Cells
Lin, P., Hsieh, H.-Y., Chu, P., & Chen, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071939 · Cited by 31
“Also, the structures, classification, biological functions, and modes of mechanism of histone deacetylase isoforms have been extensively covered [39,43,44], and they will not be discussed here.”
BackgroundEpigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase Inhibitors
Ungerstedt, J. S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103091 · Cited by 31
“The general mechanisms for HDACi induced cell death include apoptosis or autophagy, increasing ROS production and decreasing scavengers, increasing DNA damage and decreasing DNA repair, decreasing oncoprotein expression and stability and stimulating immunogenic cell death [27,40,41].”
BackgroundKim, J. K., Kan, G., Mao, Y., Wu, Z., Tan, X., He, H., & Lee, C. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12607 · Cited by 31
“One class of such inhibitors is histone deacetylase (HDAC) inhibitors, which have been under continued development for treating many diseases including cancers and neurological disorders since their excellent therapeutic efficacy was proven for treating cutaneous T cell lymphoma (Duvic et al., 2007; Falkenberg and Joh…”
BackgroundInfluentialHDAC6-selective inhibitors enhance anticancer effects of paclitaxel in ovarian cancer cells
Yoo, J. H., Jeon, Y. H., Lee, D., Kim, G. W., Lee, S. K., Kim, S., Park, J., & Kwon, S. H. (2021) · Oncology Letters · doi:10.3892/ol.2021.12462 · Cited by 32
“HDAC inhibitors have been used in multiple studies as alternatives to treat cancer; these induce cell death, cell cycle arrest, and senescence in tumor cells (31,32).”
MethodPeripheral blood lymphocyte subset levels differ in patients with hepatocellular carcinoma
Liu, H., Deng, W. W., Li, J., Tang, Y., Zhang, L., Cui, Y., & Liang, X.-Q. (2016) · Oncotarget · doi:10.18632/oncotarget.13041 · Cited by 30
Traore, M. D. M., Zwick, V., Simões‐Pires, C. A., Nurisso, A., Issa, M. E., Cuendet, M., Maynadier, M., Wein, S., Vial, H. J., Jamet, H., et al. (2017) · ACS Omega · doi:10.1021/acsomega.6b00481 · Cited by 31
Drugging the Schistosome Zinc-Dependent HDACs: Current Progress and Future Perspectives
Marek, M., Oliveira, G., Pierce, R. J., Jung, M., Sippl, W., & Romier, C. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.25 · Cited by 33
Inhibiting stromal Class I HDACs curbs pancreatic cancer progression
Liang, G., Oh, T. G., Hah, N., Tiriac, H., Shi, Y., Truitt, M., Antal, C. E., Atkins, A. R., Li, Y., Fraser, C. R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42178-6 · Cited by 35
“HDAC inhibitors are a class of epigenetic modulators currently being explored as cancer therapies 26,27 .”
BackgroundKadier, K., Niu, T., Ding, B., Chen, B., Qi, X., Chen, D., Cheng, X., Fang, Y.-Z., Zhou, J., Zhao, W., et al. (2024) · Advanced Science · doi:10.1002/advs.202309459 · Cited by 31
Olawade, D. B., Rashad, I., Egbon, E., Teke, J., Ovsepian, S. V., & Boussios, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104929 · Cited by 37
“The long-term administration of these drugs may lead to off-target effects, such as the dysregulation of non-neuronal genes, which can have systemic consequences [147].”
Conformational Analysis of Misfolded Protein Aggregation by FRET and Live-Cell Imaging Techniques
Kitamura, A., Nagata, K., & Kinjo, M. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16036076 · Cited by 31
Almaliti, J., Al-Hamashi, A. A., Negmeldin, A. T., Hanigan, C. L., Perera, L., Pflum, M. K. H., Casero, R. A., & Tillekeratne, L. M. V. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01271 · Cited by 30
Peng, U., Wang, Z., Pei, S., Ou, Y., Hu, P., Liu, W., & Song, J. (2016) · Oncology Reports · doi:10.3892/or.2016.5340 · Cited by 29
Synthesis and biological evaluation of largazole zinc-binding group analogs
Kim, B., Ratnayake, R., Lee, H., Shi, G., Zeller, S. L., Li, C., Luesch, H., & Hong, J. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.03.071 · Cited by 29
Moj, D., Britz, H., Burhenne, J., Stewart, C. F., Egerer, G., Haefeli, W. E., & Lehr, T. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3447-x · Cited by 31
“HDAC inhibitors (HDACi), such as vorinostat, show antineoplastic effects in vitro and in vivo, and offer therefore a new approach in chemotherapy [2].”
BackgroundPD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-γ
Iwasa, M., Harada, T., Oda, A., Bat‐Erdene, A., Teramachi, J., Tenshin, H., Ashtar, M., Oura, M., Sogabe, K., Udaka, K., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.26726 · Cited by 31
“Histone deacetylase (HDAC) inhibitors alter the immunogenicity and anti-tumor immune responses [11].”
HDAC1 and HDAC2 independently regulate common and specific intrinsic responses in murine enteroids
Gonneaud, A., Turgeon, N., Jones, C. M., Couture, C., Lévesque, D., Boisvert, F., Boudreau, F., & Asselin, C. (2019) · Scientific Reports · doi:10.1038/s41598-019-41842-6 · Cited by 31
Revisiting the Language of Glycoscience: Readers, Writers and Erasers in Carbohydrate Biochemistry
Dedola, S., Rugen, M. D., Young, R. J., & Field, R. A. (2019) · ChemBioChem · doi:10.1002/cbic.201900377 · Cited by 30
Elek, G. Z., Koppel, K., Zubrytski, D. M., Konrad, N., Järving, I., Lopp, M., & Kananovich, D. G. (2019) · Organic Letters · doi:10.1021/acs.orglett.9b03305 · Cited by 32
Sakloth, F., Manouras, L., Avrampou, K., Mitsi, V., Serafini, R. A., Pryce, K. D., Cogliani, V., Berton, O., Jarpe, M. B., & Zachariou, V. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05525-9 · Cited by 30
Epigenetic Mechanisms Activated by Childhood Adversity
Krause, B. J., Artigas, R., Sciolla, A., & Hamilton, J. (2020) · Epigenomics · doi:10.2217/epi-2020-0042 · Cited by 30
Rising Interest in the Development of Metal Complexes in Cancer Immunotherapy
Li, Z., Shen, Q., Mao, Z., & Tan, C. (2022) · Chemistry - An Asian Journal · doi:10.1002/asia.202200270 · Cited by 29
Role of Selective Histone Deacetylase 6 Inhibitor ACY-1215 in Cancer and Other Human Diseases
Li, J., Yu, M., Fu, S., Liu, D., & Tan, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.907981 · Cited by 32
“Due to adverse toxicity such as fatigue, diarrhea, and thrombocytopenia, their clinical application is limited (Falkenberg and Johnstone, 2014; Minucci and Pelicci, 2006).”
BackgroundThe function of histone methylation and acetylation regulators in GBM pathophysiology
McCornack, C. R., Woodiwiss, T. R., Hardi, A., Yano, H., & Kim, A. H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1144184 · Cited by 36
High-throughput small molecule screen identifies inhibitors of aberrant chromatin accessibility
Pattenden, S. G., Simon, J. M., Wali, A., Jayakody, C. N., Troutman, J. A., McFadden, A. W., Wooten, J., Wood, C. C., Frye, S. V., Janzen, W. P., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521827113 · Cited by 35
Nicholas, D., Andrieu, G. P., Strissel, K. J., Nikolajczyk, B. S., & Denis, G. V. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2320-0 · Cited by 35
Photochromic histone deacetylase inhibitors based on dithienylethenes and fulgimides
Wutz, D., Gluhacevic, D., Chakrabarti, A., Schmidtkunz, K., Robaa, D., Erdmann, F., Romier, C., Sippl, W., Jung, M., & König, B. (2017) · Organic & Biomolecular Chemistry · doi:10.1039/c7ob00976c · Cited by 31
Kim, H., Lin, Q., & Yun, Z. (2019) · Scientific Reports · doi:10.1038/s41598-019-46210-y · Cited by 28
Zhou, H., Qin, D., Xie, C., Zhou, J., Jia, S., Zhou, Z., Qiu, Y., Xu, B., & Zha, J. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0796 · Cited by 34
Wu, X., Zhang, X., Tang, S., & Wang, Y. (2025) · Cell Biology and Toxicology · doi:10.1007/s10565-024-09984-0 · Cited by 35
Touch, act and go: landing and operating on nucleosomes
Speranzini, V., Pilotto, S., Sixma, T. K., & Mattevi, A. (2016) · The EMBO Journal · doi:10.15252/embj.201593377 · Cited by 36
Huang, W. J., Zeng, C., Liu, J., Yuan, L., Liu, W., Wang, L., Zhu, H., Yang, X., Luo, Y., Xie, D., et al. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.04.111 · Cited by 32
Bedenbender, K., Scheller, N., Fischer, S., Leiting, S., Preissner, K. T., Schmeck, B., & Vollmeister, E. (2019) · The FASEB Journal · doi:10.1096/fj.201900451r · Cited by 32
Harnessing the immune system after allogeneic stem cell transplant in acute myeloid leukemia
Sterling, C. H., & Webster, J. A. (2020) · American Journal of Hematology · doi:10.1002/ajh.25750 · Cited by 30
Histone deacetylase 9 deficiency exaggerates uterine M2 macrophage polarization
Liu, Y., Du, M., & Lin, H. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16616 · Cited by 31
Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present)
He, X., Zhang, H., Zhang, Y., Ye, Y., Wang, S., Bai, R., Xie, T., & Ye, X. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114143 · Cited by 27
Duan, N., Hu, X., Qiu, H., Zhou, R., Li, Y., Lu, W., Zhu, Y., Shen, S., Wu, W., Yang, F., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06205-0 · Cited by 29
“As an important epigenetic eraser, histone deacetylases (HDACs) remove acetyl groups from the N-acetylated lysine residues in the tail of histones, resulting in chromatin condensation and impacting gene expression [6].”
Recent advances in c-Met-based dual inhibitors in the treatment of cancers
Jin, F., Lin, Y., Weidong, Y., Wu, S., Yang, M., Ding, S., Liu, J., & Chen, Y. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116477 · Cited by 31
The polycomb group protein enhancer of zeste 2 is a novel therapeutic target for cervical cancer
Ding, M., Zhang, H., Li, Z., Wang, C., Chen, J., Shi, L., Xu, D., & Gao, Y. (2015) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12382 · Cited by 30
Wen, J., Niu, Q., Liu, J., Bao, Y. J., Yang, J., Luan, S., Fan, Y., Liu, D., & Zhao, L. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.12.007 · Cited by 28
Pardo, M., Cheng, Y., Velmeshev, D., Magistri, M., Eldar-Finkelman, H., Martínez, A., Faghihi, M. A., Jope, R. S., & Beurel, E. (2017) · JCI Insight · doi:10.1172/jci.insight.91782 · Cited by 35
Discovery of a novel rhein-SAHA hybrid as a multi-targeted anti-glioblastoma drug
Chen, J., Luo, B., Wen, S., & Pi, R. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00821-4 · Cited by 28
Recent Developments in the Role of Histone Acetylation in Asthma
Potaczek, D. P., Bazan‐Socha, S., Wypasek, E., Wygrecka, M., & Garn, H. (2024) · International Archives of Allergy and Immunology · doi:10.1159/000536460 · Cited by 28
Small-molecule-based targeted therapy in liver cancer
Ming, Y., Gong, Y., Fu, X., Ouyang, X., Peng, Y., & Pu, W. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.08.001 · Cited by 32
Jurkowska, R. Z. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108732 · Cited by 34
Suda, S., Ueda, M., Nito, C., Nishiyama, Y., Okubo, S., Abe, A., Aoki, J., Suzuki, K., Sakamoto, Y., & Kimura, K. (2015) · Brain Research · doi:10.1016/j.brainres.2015.02.013 · Cited by 28
Chemopreventive Activities of Sulforaphane and Its Metabolites in Human Hepatoma HepG2 Cells
Liu, P., Wang, W., Zhou, Z., Smith, A. J. O., Bowater, R. P., Wormstone, I. M., Chen, Y., & Bao, Y. (2018) · Nutrients · doi:10.3390/nu10050585 · Cited by 31
“The activity and expression of up-regulated histone deacetylases (HDACs) may be associated with the epigenetic repression of the tumor suppressor genes and the dysregulation of cell differentiation, proliferation, apoptosis, invasion and metastasis [21].”
BackgroundFournier, J., Bhurruth-Alcor, Y., Musicki, B., Aubert, J., Aurelly, M., Bouix‐Peter, C., Bouquet, K., Chantalat, L., Delorme, M., Drean, B., et al. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.06.029 · Cited by 27
McGivern, T. J. P., Slator, C., Kellett, A., & Marmion, C. J. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00652 · Cited by 31
Hua, L., & Wakimoto, H. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1614557 · Cited by 30
“Histone deacetylases (HDAC) are involved in innate immune mechanisms and can upregulate type I IFN responses [36].”
BackgroundKinetic Tuning of HDAC Inhibitors Affords Potent Inducers of Progranulin Expression
Moreno-Yruela, C., Fass, D. M., Cheng, C., Herz, J., Olsen, C. A., & Haggarty, S. J. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00281 · Cited by 27
“‡, 10 2 (SATK) Ki = 9800 (± 6700)26 Dis. t½ = 41 (± 17) Ki = 11000 (± 4000)26 Dis. t½ = 87 (± 22) Ki, 1 = 570 (± 260)26 Ki ~1126 Dis. t½ ≥ 139 No change No change 3 (tacedinaline) Ki, 1 = 1450 (± 320) Ki ~1 Dis. t½ ≥ 1386 Ki, 1 = 2190 (± 510) Ki ~14 Dis. t½ ≥ 139 Ki, 1 = 3560 (± 400) Ki = 105 (± 86) Dis. t½ ≥ 50 Decre…”
BackgroundInfluentialRamaiah, M. J., Karthikeyan, D., Kumar, S. K., & Yamajala, R. B. R. D. (2019) · Gene · doi:10.1016/j.gene.2019.144126 · Cited by 30
Rodrigues, D. A., Pinheiro, P. D. S. M., & Fraga, C. A. M. (2020) · ChemMedChem · doi:10.1002/cmdc.202000643 · Cited by 29
Li, Y.-R., Liu, F., Liu, W., Zhang, Y., Tian, X.-Y., Fu, X.-J., Xu, Y. C., Song, J., & Zhang, S. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115070 · Cited by 27
PROTACs in gastrointestinal cancers
Chen, Y., Yang, Q., Xu, J., Tang, L., Zhang, Y., Du, F., Zhao, Y., Wu, X., Li, M., Shen, J., et al. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.10.012 · Cited by 30
“The histone deacetylase (HDAC) family of enzymes plays a key role in epigenetic regulation.(188) Thus far, 18 HDACs have been documented.”
BackgroundNepali, K., Lee, H., Lai, M.-J., Ojha, R., Wu, T.-Y., Wu, G.-X., Chen, M.-C., & Liou, J. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.12.039 · Cited by 27
Farag, A., Ewida, H. A., & Ahmed, M. S. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.02.011 · Cited by 27
How to Distinguish Between the Activity of HDAC1-3 and HDAC6 with Western Blot
Beyer, M., Kiweler, N., Mahboobi, S., & Krämer, O. H. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6527-4_26 · Cited by 26
Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy
Meyers, D. E., Wang, A. A., Thirukkumaran, C. M., & Morris, D. G. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00114 · Cited by 29
Kitadate, A., Ikeda, S., Abe, F., Takahashi, N., Shimizu, N., Matsue, K., & Tagawa, H. (2017) · Haematologica · doi:10.3324/haematol.2017.177279 · Cited by 31
“The development and clinical application of isoform-specific HDAC inhibitors are progressing.(42) Romidepsin, a class I-specific HDAC inhibitor has been shown to be clinically effective against PTCL.”
BackgroundHDAC6 interacts with PTPN1 to enhance melanoma cells progression
Liu, J., Luan, W., Zhang, Y., Gu, J., Shi, Y., Yang, Y., Feng, Z., & Qi, F. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.12.145 · Cited by 28
Yelton, C. J., & Ray, S. K. (2018) · Neuroimmunology and Neuroinflammation · doi:10.20517/2347-8659.2018.58 · Cited by 25
“Over the years, abnormal HDAC transcripts have been linked to multiple pathologies including neurological diseases, immune disorders, and a multitude of cancers[32,33].”
BackgroundRole of BRD4 phosphorylation in the nucleus accumbens in relapse to cocaine‐seeking behavior in mice
Guo, W., Long, H., Bu, Q., Zhao, Y., Wang, H., Tian, J., & Cen, X. (2019) · Addiction Biology · doi:10.1111/adb.12808 · Cited by 25
Zuo, Y., Xu, H., Chen, Z., Xiong, F., Zhang, B., Chen, K., Jiang, H., Luo, C., & Zhang, H. (2020) · Oncology Reports · doi:10.3892/or.2020.7563 · Cited by 37
Potluri, V., Shandil, R., Gavara, R., Sambasivam, G., Campo, B., Wittlin, S., & Narayanan, S. (2020) · Malaria Journal · doi:10.1186/s12936-020-03421-3 · Cited by 24
Mahajan, M., Suryavanshi, S., Bhowmick, S., Alasmary, F. A., Almutairi, T. M., Islam, M. A., & Kaul-Ghanekar, R. (2021) · Biophysical Chemistry · doi:10.1016/j.bpc.2021.106588 · Cited by 28
Epigenetic Regulation of Cancer Immune Cells
Patino, D. M. A., Radhakrishnan, V., Suvilesh, K. N., Manjunath, Y., Li, G., Kimchi, E. T., Staveley-O’Carroll, K. F., Warren, W. C., Kaifi, J. T., & Mitchem, J. B. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.022 · Cited by 27
Integrating Immunotherapy with Chemotherapy: A New Approach to Drug Repurposing
Qayoom, H., Mehraj, U., Aisha, S., Sofi, S., & Mir, M. A. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.100183 · Cited by 26
“In epigenetic therapy, drugs target three specific protein categories (a) Writers, enzymes that establish epigenetic marks; (b) Readers, proteins that recognize histone and may bring in other protein complexes to change gene expression; and (c) Erasers, enzymes that remove epigenetic marks [111].”
BackgroundChen, Y., Zou, J., Cheng, F., & Li, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.769730 · Cited by 31
Zhao, C., Zhang, Y., Zhang, J., Li, S., Liu, M.-Y., Geng, Y., Liu, F., Chai, Q., Meng, H., Li, M., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01242 · Cited by 27
Gonneaud, A., Turgeon, N., Boudreau, F., Perreault, N., Rivard, N., & Asselin, C. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25090 · Cited by 25
Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression
Wang, Q., Tan, R., Zhu, X. J., Zhang, Y., Tan, Z., Su, B., & Li, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.7134 · Cited by 27
Histone Adduction and Its Functional Impact on Epigenetics
Galligan, J. J., & Marnett, L. J. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00379 · Cited by 27
Shapira, L., Ralph-Altman, M., Tomer, E., Shai, C., & Kobiler, O. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01970 · Cited by 26
Evolutionary relationships among protein lysine deacetylases of parasites causing neglected diseases
Scholte, L., Mourão, M. D. M., Pais, F. S.-M., Melesina, J., Robaa, D., Volpini, Â. C., Sippl, W., Pierce, R. J., Oliveira, G., & Nahum, L. A. (2017) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2017.05.011 · Cited by 31
Wang, F., Zheng, L., Yi, Y., Yang, Z., Qiu, Q., Wang, X., Yan, W., Bai, P., Yang, J., Li, D., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0332 · Cited by 27
“Consisting of 11 members, the classical histone deacetylase (HDAC) enzyme family has emerged as an attractive target in cancer therapy (1).”
BackgroundNeuroepigenetics and Alzheimer’s Disease: An Update
Zusso, M., Barbierato, M., Facci, L., Skaper, S. D., & Giusti, P. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180259 · Cited by 33
Hu, J., An, B., Pan, T., Li, Z., Huang, L., & Li, X. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.10.022 · Cited by 27
Swanson, G., Estill, M. S., Diamond, M. P., Legro, R. S., Coutifaris, C., Barnhart, K. T., Huang, H., Hansen, K. R., Trussell, J. C., Coward, R. M., et al. (2019) · Epigenetics · doi:10.1080/15592294.2019.1644880 · Cited by 38
Wang, Z., Qin, W., & Yi, F. (2015) · 老年心脏病学杂志:英文版 · doi:10.11909/j.issn.1671-5411.2015.02.010 · Cited by 31
HDAC6 mediates NLRP3 inflammasome activation in the pathogenesis of diabetic retinopathy
Kim, J.-S., Jun, J. H., Lee, J.-M., Park, S., Kim, E., Hwang, S. J., Moon, H., Baek, S. H., Kim, H. K., Park, J., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156108 · Cited by 30
Identification of Epigenetic Biomarkers of Lung Adenocarcinoma through Multi-Omics Data Analysis
Kikutake, C., & Yahara, K. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152918 · Cited by 25
Reciprocal regulation between microRNAs and epigenetic machinery in colorectal cancer
Wang, F., Ma, Y., Wang, H., & Qin, H. (2017) · Oncology Letters · doi:10.3892/ol.2017.5593 · Cited by 28
Metadata
- Authors
- Falkenberg, K. J., & Johnstone, R. W.
- Affiliations
- Peter MacCallum Cancer Centre (AU)
- The University of Melbourne (AU)
- Corresponding author
- Johnstone, Ricky W.
- ORCID
- Johnstone, Ricky W.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-08-18
- Volume
- 13
- Issue
- 9
- Pages
- 673-691
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2046345187
- Cited by
- 1,564
- References
- 281
- Citations by year
- 2026: 82 · 2025: 110 · 2024: 89 · 2023: 96 · 2022: 121 · 2021: 133 · 2020: 160 · 2019: 146 · 2018: 134 · 2017: 166 · 2016: 208 · 2015: 108 · 2014: 8
- FWCI
- 15.82
- Type
- journal article
- Language
- en
- Update notices
- addendum (2015-02-27)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- histone deacetylase, histone deacetylase inhibitors, epigenetic regulation, cancer, neurological disorders, immune disorders, small molecule inhibitors, lysine deacetylation, epigenetic aberrations, drug development
- MeSH terms
- Animals, Histone Deacetylases, Humans, Immune System Diseases, Neoplasms, Nervous System Diseases, Epigenesis, Genetic, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.